Company News: Abbott and Solvay Pharmaceuticals

Share this article:
Abbott completed its $6.2 billion acquisition of Solvay Pharmaceuticals, and said it expects the acquisition to add about $2.9 billion to 2010 sales, mostly outside the US, and around $500 million to the company's annual R&D investment. “In addition to taking both Abbott and Solvay products into new and expanding markets, the acquisition enhances our R&D investment, providing Abbott with the opportunity to drive future pharmaceutical growth,” said Abbott chairman and CEO Miles White in a statement.
Share this article:
You must be a registered member of MMM to post a comment.

Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.